Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656239 · ClinicalTrials.gov registry record · Phase 2
Dose Range Finding Study of Fedovapagon in Men With Nocturia
A Phase 2 study, sponsored by Vantia.
- Completed
- Registry status
- Phase 2
- Development phase
- 358
- Enrollment target
NCT01656239: Completed Phase 2 study, sponsored by Vantia.
NCT01656239 is a Phase 2 study that has completed, run by Vantia. The registered enrollment target is 358 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (169% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01656239, a Phase 2 study, has completed, sponsored by Vantia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 358 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.
Interventions
- DRUG fedovapagon 1 mg
- DRUG fedovapagon 2 mg
- DRUG fedovapagon 4 mg
- DRUG Placebo ( sugar pill)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
What the finished NCT01656239 record still lists
NCT01656239 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (169% higher).
The record links to 0 conditions, and to 4 interventions - of which fedovapagon 1 mg is the first listed.
NCT01656239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01656239 about?
NCT01656239 is a clinical study titled "Dose Range Finding Study of Fedovapagon in Men With Nocturia". The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.
What is the current status of trial NCT01656239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 358 participants. The study started on 2012-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01656239?
The interventions under investigation include: fedovapagon 1 mg (DRUG), fedovapagon 2 mg (DRUG), fedovapagon 4 mg (DRUG), Placebo ( sugar pill) (DRUG).
Who is sponsoring clinical trial NCT01656239?
This trial is sponsored by Vantia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01656239's enrollment target sits among peer trials
358 127th of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373317 · 358 participants · Phase 4
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- NCT05684965 · 358 participants · Phase 1
XTX301 in Patients With Advanced Solid Tumors
- NCT05824975 · 358 participants · Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- NCT06480227 · 358 participants · NA
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia